ApprovalTrail

Drug · DIN 02320541

SYNFLORIX

No: no longer authorized

The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.

Status Cancelled Post Market since September 30, 2025; first marketed May 22, 2009.
Drug Identification Number (DIN)
02320541
Company (DIN owner)
Glaxosmithkline IncMississauga, Ontario, Canada
Schedule
Schedule D
Dosage form
Suspension
Route
Intramuscular
Therapeutic class (ATC)
Pneumococcus, purified polysacc.antigen conjugated J07AL02
Class
Human
Record last updated
April 27, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO PROTEIN D CARRIER PROTEIN3 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML
PNEUMOCOCCAL POLYSACC. SEROT. 18C CONJUG. TO TETANUS TOXOID CARRIER PROT.3 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARID SEROT. 19F CONJUG. TO DIPHTHERIA TOXOID CARRIER PROT.3 MCG0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO PROTEIN D CARRIER PROTEIN1 MCG0.5 ML

Notices of Compliance

Health Canada approvals that name this DIN.